Trimetazidine ameliorates sunitinib-induced cardiotoxicity in mice via the AMPK/mTOR/autophagy pathway

References

• Chen J, Lai J, Yang L, Ruan G, Chaugai S, Ning Q, Chen C, Wang DW. 2016. Trimetazidine prevents macrophage-mediated septic myocardial dysfunction via activation of the histone deacetylase sirtuin 1. Brit J Pharmacol. 173(3):545–561.
   PubMed Web of Science ®Google Scholar
• Chintalgattu V, Rees ML, Culver JC, Goel A, Jiffar T, Zhang J, Dunner K, Jr., Pati S, Bankson JA, Pasqualini R, et al. 2013. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med. 5(187):187–169.
   Web of Science ®Google Scholar
• Chrusciel P, Rysz J, Banach M. 2014. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs. 74(9):971–980.
   PubMed Web of Science ®Google Scholar
• Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, et al. 2007. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 370(9604):2011–2019.
   PubMed Web of Science ®Google Scholar
• DeVorkin L, Hattersley M, Kim P, Ries J, Spowart J, Anglesio MS, Levi SM, Huntsman DG, Amaravadi RK, Winkler JD, et al. 2017. Autophagy inhibition enhances sunitinib efficacy in clear cell ovarian carcinoma. Mol Cancer Res. 15(3):250–258.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Autorino R, Bruni G, Carteni G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, et al. 2009. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 20(9):1535–1542.
   PubMed Web of Science ®Google Scholar
• Dyczynski M, Yu Y, Otrocka M, Parpal S, Braga T, Henley AB, Zazzi H, Lerner M, Wennerberg K, Viklund J, et al. 2018. Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to sunitinib. Cancer Lett. 435:32–43.
   PubMed Web of Science ®Google Scholar
• Ewer MS, Suter TM, Lenihan DJ, Niculescu L, Breazna A, Demetri GD, Motzer RJ. 2014. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur J Cancer. 50(12):2162–2170.
   PubMed Web of Science ®Google Scholar
• Ferraro E, Giammarioli AM, Caldarola S, Lista P, Feraco A, Tinari A, Salvatore AM, Malorni W, Berghella L, Rosano G. 2013. The metabolic modulator trimetazidine triggers autophagy and counteracts stress-induced atrophy in skeletal muscle myotubes. Febs J. 280(20):5094–5108.
   PubMed Web of Science ®Google Scholar
• Gál I, Varga T, Szilágyi I, Balázs M, Schlammadinger J, Szabó G. 2000. Protease-elicited TUNEL positivity of non-apoptotic fixed cells. J Histochem Cytochem. 48(7):963–970.
   PubMed Web of Science ®Google Scholar
• Gao S, Ho D, Vatner DE, Vatner SF. 2011. Echocardiography in mice. Curr Protoc Mouse Biol. 1:71–83.
   PubMedGoogle Scholar
• Gong W, Ma Y, Li A, Shi H, Nie S. 2018. Trimetazidine suppresses oxidative stress, inhibits MMP-2 and MMP-9 expression, and prevents cardiac rupture in mice with myocardial infarction. Cardiovasc Ther. 36(5):e12460.
   PubMed Web of Science ®Google Scholar
• Halama A, Kulinski M, Dib SS, Zaghlool SB, Siveen KS, Iskandarani A, Zierer J, Prabhu KS, Satheesh NJ, Bhagwat AM, et al. 2018. Accelerated lipid catabolism and autophagy are cancer survival mechanisms under inhibited glutaminolysis. Cancer Lett. 430:133–147.
   PubMed Web of Science ®Google Scholar
• Jacob F, Yonis AY, Cuello F, Luther P, Schulze T, Eder A, Streichert T, Mannhardt I, Hirt MN, Schaaf S, et al. 2016. Analysis of tyrosine kinase inhibitor-mediated decline in contractile force in rat engineered heart tissue. PLOS One. 11(2):e0145937.
   PubMed Web of Science ®Google Scholar
• Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF, Beahm C, Chen MH, Force T. 2009. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci. 2(1):15–25.
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, et al. 2016. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12(1):1–222.
   PubMed Web of Science ®Google Scholar
• Korashy HM, Al-Suwayeh HA, Maayah ZH, Ansari MA, Ahmad SF, Bakheet SA. 2015. Mitogen-activated protein kinases pathways mediate the sunitinib-induced hypertrophy in rat cardiomyocyte H9c2 cells. Cardiovasc Toxicol. 15(1):41–51.
   PubMed Web of Science ®Google Scholar
• Lopatin YM, Rosano GM, Fragasso G, Lopaschuk GD, Seferovic PM, Gowdak LH, Vinereanu D, Hamid MA, Jourdain P, Ponikowski P. 2016. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. Int J Cardiol. 203:909–915.
   PubMed Web of Science ®Google Scholar
• Maayah ZH, Ansari MA, El Gendy MA, Al-Arifi MN, Korashy HM. 2014. Development of cardiac hypertrophy by sunitinib in vivo and in vitro rat cardiomyocytes is influenced by the aryl hydrocarbon receptor signaling pathway. Arch Toxicol. 88(3):725–738.
   PubMed Web of Science ®Google Scholar
• Mele D, Nardozza M, Spallarossa P, Frassoldati A, Tocchetti CG, Cadeddu C, Madonna R, Malagù M, Ferrari R, Mercuro G. 2016. Current views on anthracycline cardiotoxicity. Heart Fail Rev. 21(5):621–634.
   PubMed Web of Science ®Google Scholar
• Molinari F, Pin F, Gorini S, Chiandotto S, Pontecorvo L, Penna F, Rizzuto E, Pisu S, Musarò A, Costelli P, et al. 2017. The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice. J Cachexia Sarcopenia Muscle. 8(6):954–973.
   PubMed Web of Science ®Google Scholar
• Narayan V, Keefe S, Haas N, Wang L, Puzanov I, Putt M, Catino A, Fang J, Agarwal N, Hyman D, et al. 2017. Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma. Clin Cancer Res. 23(14):3601–3609.
   PubMed Web of Science ®Google Scholar
• Ravaud A, de la Fouchardière C, Caron P, Doussau A, Do Cao C, Asselineau J, Rodien P, Pouessel D, Nicolli-Sire P, Klein M, et al. 2017. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur J Cancer. 76:110–117.
   PubMed Web of Science ®Google Scholar
• Reichardt P, Kang YK, Rutkowski P, Schuette J, Rosen LS, Seddon B, Yalcin S, Gelderblom H, Williams CC Jr., Fumagalli E, et al. 2015. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 121(9):1405–1413.
   PubMed Web of Science ®Google Scholar
• Stuhlmiller TJ, Zawistowski JS, Chen X, Sciaky N, Angus SP, Hicks ST, Parry TL, Huang W, Beak JY, Willis MS, et al. 2017. Kinome and transcriptome profiling reveal broad and distinct activities of erlotinib, sunitinib, and sorafenib in the mouse heart and suggest cardiotoxicity from combined signal transducer and activator of transcription and epidermal growth factor receptor inhibition. J Am Heart Assoc. 6(10):1–23.
   Web of Science ®Google Scholar
• Tallarico D, Rizzo V, Di Maio F, Petretto F, Bianco G, Placanica G, Marziali M, Paravati V, Gueli N, Meloni F, et al. 2003. Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy. Angiology. 54(2):219–227.
   PubMed Web of Science ®Google Scholar
• Thakur PC, Miller-Ocuin JL, Nguyen K, Matsuda R, Singhi AD, Zeh HJ, Bahary N. 2018. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. J Transl Med. 16(1):190.
   PubMed Web of Science ®Google Scholar
• Varga ZV, Ferdinandy P, Liaudet L, Pacher P. 2015. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol. 309(9):H1453–H1467.
   PubMed Web of Science ®Google Scholar
• Washington Institute for Laboratory Animal Research. 2011. Guide for the care and use of laboratory animals. Washington (DC): National Academies Press.
   Google Scholar
• Wu S, Chang G, Gao L, Jiang D, Wang L, Li G, Luo X, Qin S, Guo X, Zhang D. 2018. Trimetazidine protects against myocardial ischemia/reperfusion injury by inhibiting excessive autophagy. J Mol Med. 96(8):791–806.
   PubMed Web of Science ®Google Scholar
• Zaouali MA, Boncompagni E, Reiter RJ, Bejaoui M, Freitas I, Pantazi E, Folch-Puy E, Abdennebi HB, Garcia-Gil FA, Roselló-Catafau J. 2013. AMPK involvement in endoplasmic reticulum stress and autophagy modulation after fatty liver graft preservation: a role for melatonin and trimetazidine cocktail. J Pineal Res. 55(1):65–78.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ding WY, Wang ZH, Tang MX, Wang F, Li Y, Zhong M, Zhang Y, Zhang W. 2016. Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy. J Transl Med. 14(1):109–120.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xue T, Yang X, Zhu H, Ding X, Lou L, Lu W, Yang B, He Q. 2010. Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells. Toxicol Appl Pharmacol. 248(1):20–27.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Zhong P, He S, Zhang Y, Tang L, Ling Y, Fu S, Tang Y, Yang P, Luo T, et al. 2017. Trimetazidine protects cardiomyocytes against hypoxia/reoxygenation injury by promoting AMP-activated protein kinase-dependent autophagic flux. J Cardiovasc Pharmacol. 69(6):389–397.
   PubMed Web of Science ®Google Scholar
• Zou H, Zhu XX, Ding YH, Jin QY, Qian LY, Huang DS, Cen XJ. 2017. Trimetazidine in conditions other than coronary disease, old drug, new tricks? Int J Cardiol. 234:1–6.
   PubMed Web of Science ®Google Scholar